Skip to main content
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Artiva Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
 20232022
Net Income
-28.72-58.79
Depreciation & Amortization
2.271.16
Share-Based Compensation
7.056.58
Other Operating Activities
-28.030.22
Operating Cash Flow
-47.43-50.83
Capital Expenditures
-3.26-6.3
Change in Investments
-22.72-
Investing Cash Flow
-25.98-6.3
Share Issuance / Repurchase
24.390.33
Other Financing Activities
--1.59
Financing Cash Flow
24.39-1.26
Net Cash Flow
-49.01-58.39
Free Cash Flow
-50.69-57.13
Free Cash Flow Margin
-151.34%-1158.55%
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).